|
US7888121B2
(en)
*
|
2003-08-08 |
2011-02-15 |
Sangamo Biosciences, Inc. |
Methods and compositions for targeted cleavage and recombination
|
|
US11311574B2
(en)
|
2003-08-08 |
2022-04-26 |
Sangamo Therapeutics, Inc. |
Methods and compositions for targeted cleavage and recombination
|
|
RU2712833C2
(ru)
|
2009-10-22 |
2020-01-31 |
ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи |
Конструируемые белки с цинковыми пальцами, направленные на гены растений, вовлеченные в биосинтез жирных кислот
|
|
US9273283B2
(en)
*
|
2009-10-29 |
2016-03-01 |
The Trustees Of Dartmouth College |
Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
|
|
US12492376B2
(en)
|
2009-10-29 |
2025-12-09 |
The Trustees Of Dartmouth College |
T-cell receptor-deficient T cell compositions
|
|
WO2011059836A2
(en)
|
2009-10-29 |
2011-05-19 |
Trustees Of Dartmouth College |
T cell receptor-deficient t cell compositions
|
|
DK2699593T4
(da)
|
2011-04-20 |
2021-02-08 |
Univ Washington Through Its Center For Commercialization |
Beta-2 mikroglobulin-deficiente celler
|
|
WO2013016446A2
(en)
|
2011-07-25 |
2013-01-31 |
Sangamo Biosciences, Inc. |
Methods and compositions for alteration of a cystic fibrosis transmembrane conductance regulator (cftr) gene
|
|
WO2013033626A2
(en)
|
2011-08-31 |
2013-03-07 |
Trustees Of Dartmouth College |
Nkp30 receptor targeted therapeutics
|
|
WO2013074916A1
(en)
|
2011-11-18 |
2013-05-23 |
Board Of Regents, The University Of Texas System |
Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla
|
|
US10704021B2
(en)
|
2012-03-15 |
2020-07-07 |
Flodesign Sonics, Inc. |
Acoustic perfusion devices
|
|
US9637739B2
(en)
|
2012-03-20 |
2017-05-02 |
Vilnius University |
RNA-directed DNA cleavage by the Cas9-crRNA complex
|
|
PT2838548T
(pt)
*
|
2012-04-17 |
2023-10-13 |
Univ Washington Through Its Center For Commercialization |
Células deficientes em hla de classe ii, células deficientes em hla de classe i capazes de expressar proteínas de hla de classe ii, e utilizações das mesmas
|
|
CN104364380B
(zh)
|
2012-04-25 |
2018-10-09 |
瑞泽恩制药公司 |
核酸酶介导的使用大靶向载体的靶向
|
|
JP6389166B2
(ja)
|
2012-05-07 |
2018-09-12 |
トラスティーズ・オブ・ダートマス・カレッジ |
抗ｂ７−ｈ６抗体、融合タンパク質、及びこれらを使用する方法
|
|
SG10201806573TA
(en)
|
2012-05-25 |
2018-09-27 |
Cellectis |
Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
|
|
US20150017136A1
(en)
*
|
2013-07-15 |
2015-01-15 |
Cellectis |
Methods for engineering allogeneic and highly active t cell for immunotherapy
|
|
US10648001B2
(en)
|
2012-07-11 |
2020-05-12 |
Sangamo Therapeutics, Inc. |
Method of treating mucopolysaccharidosis type I or II
|
|
AU2013329186B2
(en)
|
2012-10-10 |
2019-02-14 |
Sangamo Therapeutics, Inc. |
T cell modifying compounds and uses thereof
|
|
US20140115728A1
(en)
|
2012-10-24 |
2014-04-24 |
A. Joseph Tector |
Double knockout (gt/cmah-ko) pigs, organs and tissues
|
|
EP4282970A3
(en)
|
2012-12-17 |
2024-01-17 |
President and Fellows of Harvard College |
Rna-guided human genome engineering
|
|
CA2904210C
(en)
*
|
2013-03-12 |
2022-07-19 |
Sangamo Biosciences, Inc. |
Methods and compositions for modification of hla
|
|
US9499855B2
(en)
|
2013-03-14 |
2016-11-22 |
Elwha Llc |
Compositions, methods, and computer systems related to making and administering modified T cells
|
|
US9587237B2
(en)
|
2013-03-14 |
2017-03-07 |
Elwha Llc |
Compositions, methods, and computer systems related to making and administering modified T cells
|
|
WO2014153470A2
(en)
*
|
2013-03-21 |
2014-09-25 |
Sangamo Biosciences, Inc. |
Targeted disruption of t cell receptor genes using engineered zinc finger protein nucleases
|
|
EP3789487A1
(en)
*
|
2013-04-03 |
2021-03-10 |
Memorial Sloan Kettering Cancer Center |
Effective generation of tumor-targeted t-cells derived from pluripotent stem cells
|
|
CA2908697C
(en)
|
2013-04-16 |
2023-12-12 |
Regeneron Pharmaceuticals, Inc. |
Targeted modification of rat genome
|
|
US11077144B2
(en)
|
2013-05-13 |
2021-08-03 |
Cellectis |
CD19 specific chimeric antigen receptor and uses thereof
|
|
EP2997134B1
(en)
|
2013-05-14 |
2020-06-24 |
Board of Regents, The University of Texas System |
Human application of engineered chimeric antigen receptor (car) t-cells
|
|
WO2014190273A1
(en)
|
2013-05-24 |
2014-11-27 |
Board Of Regents, The University Of Texas System |
Chimeric antigen receptor-targeting monoclonal antibodies
|
|
CA2926078C
(en)
|
2013-10-17 |
2021-11-16 |
Sangamo Biosciences, Inc. |
Delivery methods and compositions for nuclease-mediated genome engineering in hematopoietic stem cells
|
|
SG10201700961TA
(en)
|
2013-12-11 |
2017-04-27 |
Regeneron Pharma |
Methods and compositions for the targeted modification of a genome
|
|
CA2931684C
(en)
|
2013-12-19 |
2024-02-20 |
Novartis Ag |
Human mesothelin chimeric antigen receptors and uses thereof
|
|
US9725710B2
(en)
|
2014-01-08 |
2017-08-08 |
Flodesign Sonics, Inc. |
Acoustophoresis device with dual acoustophoretic chamber
|
|
CN106414748B
(zh)
|
2014-02-14 |
2021-05-28 |
得克萨斯州大学系统董事会 |
嵌合抗原受体及制备方法
|
|
US10836998B2
(en)
|
2014-02-14 |
2020-11-17 |
Cellectis |
Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells
|
|
WO2015136001A1
(en)
|
2014-03-11 |
2015-09-17 |
Cellectis |
Method for generating t-cells compatible for allogenic transplantation
|
|
JP2017513818A
(ja)
|
2014-03-15 |
2017-06-01 |
ノバルティス アーゲー |
キメラ抗原受容体を使用する癌の処置
|
|
CA2943008C
(en)
|
2014-03-19 |
2021-03-30 |
Cellectis |
Cd123 specific chimeric antigen receptors for cancer immunotherapy
|
|
SI3888674T1
(sl)
|
2014-04-07 |
2024-08-30 |
Novartis Ag |
Zdravljenje raka z uporabo antigenskega himernega receptorja proti-CD19
|
|
EP3129473B8
(en)
|
2014-04-11 |
2020-12-23 |
Cellectis |
Method for generating immune cells resistant to arginine and/or tryptophan depleted microenvironment
|
|
AU2015248956B2
(en)
*
|
2014-04-14 |
2020-06-25 |
Cellectis |
BCMA (CD269) specific chimeric antigen receptors for cancer immunotherapy
|
|
CA2945393C
(en)
*
|
2014-04-24 |
2021-03-23 |
Board Of Regents, The University Of Texas System |
Application of induced pluripotent stem cells to generate adoptive cell therapy products
|
|
HUE049776T2
(hu)
|
2014-06-06 |
2020-10-28 |
Regeneron Pharma |
Módszerek és készítmények egy célzott lókusz módosítására
|
|
EP3161128B1
(en)
|
2014-06-26 |
2018-09-26 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for targeted genetic modifications and methods of use
|
|
GB201412494D0
(en)
*
|
2014-07-14 |
2014-08-27 |
Ospedale San Raffaele And Fond Telethon |
Vector production
|
|
SG10201913765YA
(en)
|
2014-07-21 |
2020-03-30 |
Novartis Ag |
Treatment of cancer using a cd33 chimeric antigen receptor
|
|
WO2016014553A1
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
|
EP3193915A1
(en)
|
2014-07-21 |
2017-07-26 |
Novartis AG |
Combinations of low, immune enhancing. doses of mtor inhibitors and cars
|
|
US10174095B2
(en)
|
2014-07-21 |
2019-01-08 |
Novartis Ag |
Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor
|
|
US9757420B2
(en)
|
2014-07-25 |
2017-09-12 |
Sangamo Therapeutics, Inc. |
Gene editing for HIV gene therapy
|
|
WO2016019144A2
(en)
|
2014-07-30 |
2016-02-04 |
Sangamo Biosciences, Inc. |
Gene correction of scid-related genes in hematopoietic stem and progenitor cells
|
|
EP4205749A1
(en)
|
2014-07-31 |
2023-07-05 |
Novartis AG |
Subset-optimized chimeric antigen receptor-containing cells
|
|
AU2015301460B2
(en)
|
2014-08-14 |
2021-04-08 |
Novartis Ag |
Treatment of cancer using GFR alpha-4 chimeric antigen receptor
|
|
RU2020117196A
(ru)
|
2014-08-19 |
2020-10-15 |
Новартис Аг |
Химерный антигенный рецептор (car) против cd123 для использования в лечении злокачественных опухолей
|
|
CN113699113A
(zh)
|
2014-09-16 |
2021-11-26 |
桑格摩治疗股份有限公司 |
用于造血干细胞中核酸酶介导的基因组工程化和校正的方法和组合物
|
|
JP6839074B2
(ja)
|
2014-09-17 |
2021-03-03 |
ノバルティス アーゲー |
養子免疫療法のためのキメラ受容体での細胞毒性細胞のターゲティング
|
|
IL297773B2
(en)
*
|
2014-11-17 |
2024-07-01 |
Adicet Bio Inc |
Engineered gamma delta t-cells
|
|
EP3221457B1
(en)
|
2014-11-21 |
2019-03-20 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for targeted genetic modification using paired guide rnas
|
|
EP3025719B1
(en)
|
2014-11-26 |
2018-09-26 |
Miltenyi Biotec GmbH |
Combination immunotherapy of antigen-recognizing receptors and hematopoietic cells for the treatment of diseases
|
|
US10889834B2
(en)
|
2014-12-15 |
2021-01-12 |
Sangamo Therapeutics, Inc. |
Methods and compositions for enhancing targeted transgene integration
|
|
JP6840077B2
(ja)
|
2014-12-19 |
2021-03-10 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
単一ステップの複数標的化を通じた標的化された遺伝子修飾のための方法及び組成物
|
|
CN107208055B
(zh)
*
|
2015-01-17 |
2021-06-15 |
浙江大学 |
引起免疫原性反应降低的被修饰细胞
|
|
EP3247366A4
(en)
|
2015-01-21 |
2018-10-31 |
Sangamo Therapeutics, Inc. |
Methods and compositions for identification of highly specific nucleases
|
|
EP3250680A4
(en)
|
2015-01-26 |
2018-12-05 |
Fate Therapeutics, Inc. |
Methods and compositions for inducing hematopoietic cell differentiation
|
|
EP3286211A1
(en)
|
2015-04-23 |
2018-02-28 |
Novartis AG |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
|
US11377651B2
(en)
|
2016-10-19 |
2022-07-05 |
Flodesign Sonics, Inc. |
Cell therapy processes utilizing acoustophoresis
|
|
US11708572B2
(en)
|
2015-04-29 |
2023-07-25 |
Flodesign Sonics, Inc. |
Acoustic cell separation techniques and processes
|
|
US10179918B2
(en)
|
2015-05-07 |
2019-01-15 |
Sangamo Therapeutics, Inc. |
Methods and compositions for increasing transgene activity
|
|
EP3294866A4
(en)
*
|
2015-05-12 |
2018-12-05 |
Sangamo Therapeutics, Inc. |
Nuclease-mediated regulation of gene expression
|
|
US9957501B2
(en)
|
2015-06-18 |
2018-05-01 |
Sangamo Therapeutics, Inc. |
Nuclease-mediated regulation of gene expression
|
|
WO2016210280A1
(en)
*
|
2015-06-26 |
2016-12-29 |
Indiana University Research & Technology Corporation |
Transgenic pigs with genetic modifications of sla
|
|
AU2016291778B2
(en)
|
2015-07-13 |
2021-05-06 |
Sangamo Therapeutics, Inc. |
Delivery methods and compositions for nuclease-mediated genome engineering
|
|
MX2018001776A
(es)
|
2015-08-11 |
2018-06-06 |
Cellectis |
Celulas para inmunoterapia modificadas geneticamente para dirigirse al antigeno cd38 y para la inactivacion del gen cd38.
|
|
US10435441B2
(en)
|
2015-09-23 |
2019-10-08 |
Sangamo Therapeutics, Inc. |
HTT repressors and uses thereof
|
|
DK3359184T3
(da)
|
2015-10-05 |
2020-06-15 |
Prec Biosciences Inc |
Genetisk modificerede celler, der omfatter et modificeret gen fra konstant alfaregion i human t-cellereceptor
|
|
DK3359660T3
(en)
|
2015-10-05 |
2020-02-17 |
Prec Biosciences Inc |
Engineered meganucleases with recognition sequences found in the human t cell receptor alpha constant region gene
|
|
MX2018004546A
(es)
|
2015-10-16 |
2019-04-15 |
Univ Columbia |
Composiciones y métodos para la inhibicion de antígenos específicos de linaje.
|
|
KR102766526B1
(ko)
|
2015-10-28 |
2025-02-13 |
상가모 테라퓨틱스, 인코포레이티드 |
간-특이적 작제물인, 인자 viii 발현 카세트 및 이의 사용 방법
|
|
AU2016349504B2
(en)
|
2015-11-04 |
2023-02-09 |
Fate Therapeutics, Inc. |
Genomic engineering of pluripotent cells
|
|
SG11201803145RA
(en)
|
2015-11-04 |
2018-05-30 |
Fate Therapeutics Inc |
Methods and compositions for inducing hematopoietic cell differentiation
|
|
JP6976249B2
(ja)
|
2015-11-23 |
2021-12-08 |
サンガモ セラピューティクス， インコーポレイテッド |
免疫を工学操作するための方法および組成物
|
|
IL259576B
(en)
|
2015-12-04 |
2022-09-01 |
Novartis Ag |
grna molecule containing tracr and crrna, pharmaceutical composition containing it and method for preparing cells for immunotherapy
|
|
WO2017106528A2
(en)
|
2015-12-18 |
2017-06-22 |
Sangamo Biosciences, Inc. |
Targeted disruption of the t cell receptor
|
|
MX2018007519A
(es)
|
2015-12-18 |
2019-09-04 |
Sangamo Therapeutics Inc |
Alteracion dirigida del receptor celular del complejo mayor de histocompatibilidad (mhc).
|
|
CN109072195A
(zh)
|
2015-12-30 |
2018-12-21 |
诺华股份有限公司 |
具有增强功效的免疫效应细胞疗法
|
|
ES2895430T3
(es)
|
2016-01-15 |
2022-02-21 |
Univ Minnesota |
Métodos y composiciones para el tratamiento de enfermedad neurológica
|
|
JP7012650B2
(ja)
|
2016-02-02 |
2022-01-28 |
サンガモ セラピューティクス， インコーポレイテッド |
Ｄｎａ結合ドメインと切断ドメインとを連結するための組成物
|
|
SG11201808831TA
(en)
|
2016-04-15 |
2018-11-29 |
Memorial Sloan Kettering Cancer Center |
Transgenic t cell and chimeric antigen receptor t cell compositions and related methods
|
|
CN109715808A
(zh)
|
2016-04-15 |
2019-05-03 |
诺华股份有限公司 |
用于选择性蛋白质表达的组合物和方法
|
|
US11214789B2
(en)
|
2016-05-03 |
2022-01-04 |
Flodesign Sonics, Inc. |
Concentration and washing of particles with acoustics
|
|
AU2017261804A1
(en)
|
2016-05-12 |
2018-11-29 |
Adicet Therapeutics, Inc. |
Methods for selective expansion of γδ T-cell populations and compositions thereof
|
|
CN109475109B
(zh)
|
2016-05-20 |
2021-10-29 |
瑞泽恩制药公司 |
用于使用多个引导rna来破坏免疫耐受性的方法
|
|
US20190336504A1
(en)
|
2016-07-15 |
2019-11-07 |
Novartis Ag |
Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
|
|
SG11201901364VA
(en)
|
2016-08-24 |
2019-03-28 |
Sangamo Therapeutics Inc |
Engineered target specific nucleases
|
|
CR20190098A
(es)
|
2016-08-24 |
2019-04-30 |
Sangamo Therapeutics Inc |
Regulación de la expresión génica usando nucleasas modificadas
|
|
WO2018049009A2
(en)
|
2016-09-07 |
2018-03-15 |
Sangamo Therapeutics, Inc. |
Modulation of liver genes
|
|
US20190203230A1
(en)
|
2016-09-28 |
2019-07-04 |
Novartis Ag |
Porous membrane-based macromolecule delivery system
|
|
JP7042263B2
(ja)
|
2016-10-20 |
2022-03-25 |
サンガモ セラピューティクス， インコーポレイテッド |
ファブリー病の治療のための方法および組成物
|
|
WO2018081531A2
(en)
|
2016-10-28 |
2018-05-03 |
Ariad Pharmaceuticals, Inc. |
Methods for human t-cell activation
|
|
EP3532106A4
(en)
|
2016-10-31 |
2020-06-24 |
Sangamo Therapeutics, Inc. |
GENERAL CORRECTION OF SCID-ASSOCIATED GENES IN HEMOTOPOIETIC STEM CELLS AND PROCUREMENT CELLS
|
|
WO2018083606A1
(en)
|
2016-11-01 |
2018-05-11 |
Novartis Ag |
Methods and compositions for enhancing gene editing
|
|
EP3346001A1
(en)
|
2017-01-06 |
2018-07-11 |
TXCell |
Monospecific regulatory t cell population with cytotoxicity for b cells
|
|
WO2018127585A1
(en)
|
2017-01-06 |
2018-07-12 |
Txcell |
Monospecific regulatory t cell population with cytotoxicity for b cells
|
|
EP3574005B1
(en)
|
2017-01-26 |
2021-12-15 |
Novartis AG |
Cd28 compositions and methods for chimeric antigen receptor therapy
|
|
BR112019017751A2
(pt)
|
2017-02-28 |
2020-04-07 |
Vor Biopharma, Inc. |
composições e métodos de inibição de proteínas de linhagem específica
|
|
US20200048359A1
(en)
|
2017-02-28 |
2020-02-13 |
Novartis Ag |
Shp inhibitor compositions and uses for chimeric antigen receptor therapy
|
|
CA3054621A1
(en)
|
2017-03-22 |
2018-09-27 |
Novartis Ag |
Compositions and methods for immunooncology
|
|
US12058986B2
(en)
|
2017-04-20 |
2024-08-13 |
Egenesis, Inc. |
Method for generating a genetically modified pig with inactivated porcine endogenous retrovirus (PERV) elements
|
|
US20200179511A1
(en)
|
2017-04-28 |
2020-06-11 |
Novartis Ag |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
|
WO2018201056A1
(en)
|
2017-04-28 |
2018-11-01 |
Novartis Ag |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
|
WO2018200943A1
(en)
|
2017-04-28 |
2018-11-01 |
Acuitas Therapeutics, Inc. |
Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
|
CA3059793A1
(en)
|
2017-05-03 |
2018-11-08 |
Sangamo Therapeutics, Inc. |
Methods and compositions for modification of a cystic fibrosis transmembrane conductance regulator (cftr) gene
|
|
US11512287B2
(en)
|
2017-06-16 |
2022-11-29 |
Sangamo Therapeutics, Inc. |
Targeted disruption of T cell and/or HLA receptors
|
|
CA3068465A1
(en)
|
2017-06-30 |
2019-01-03 |
Precision Biosciences, Inc. |
Genetically-modified t cells comprising a modified intron in the t cell receptor alpha gene
|
|
EP3645721A1
(en)
|
2017-06-30 |
2020-05-06 |
Novartis AG |
Methods for the treatment of disease with gene editing systems
|
|
WO2019032675A1
(en)
|
2017-08-08 |
2019-02-14 |
Sangamo Therapeutics, Inc. |
CELL TARGETING MEDIATED BY A CHIMERIC ANTIGEN RECEPTOR
|
|
CA3076337A1
(en)
|
2017-09-19 |
2019-03-28 |
Massachusetts Institute Of Technology |
Compositions for chimeric antigen receptor t cell therapy and uses thereof
|
|
WO2019056099A1
(en)
|
2017-09-19 |
2019-03-28 |
The University Of British Columbia |
ANTI-HLA-A2 ANTIBODIES AND METHODS OF USE
|
|
WO2019056106A1
(en)
|
2017-09-20 |
2019-03-28 |
The University Of British Columbia |
NOVEL ANTI-HLA-A2 ANTIBODIES AND USES THEREOF
|
|
US20210179709A1
(en)
|
2017-10-31 |
2021-06-17 |
Novartis Ag |
Anti-car compositions and methods
|
|
JP2021502085A
(ja)
|
2017-11-09 |
2021-01-28 |
サンガモ セラピューティクス， インコーポレイテッド |
サイトカイン誘導性ｓｈ２含有タンパク質（ｃｉｓｈ）遺伝子の遺伝子改変
|
|
AU2018370120C1
(en)
|
2017-11-15 |
2024-05-30 |
Adicet Therapeutics, Inc. |
Methods for selective expansion of d3 yd T-cell populations and compositions thereof
|
|
WO2019104245A1
(en)
|
2017-11-22 |
2019-05-31 |
La Jolla Institute For Allergy And Immunology |
Use and production of engineered immune cells
|
|
JP2021507561A
(ja)
|
2017-12-14 |
2021-02-22 |
フロデザイン ソニックス， インク．Ｆｌｏｄｅｓｉｇｎ Ｓｏｎｉｃｓ， Ｉｎｃ． |
音響トランスデューサドライバ及びコントローラ
|
|
WO2019133881A1
(en)
|
2017-12-29 |
2019-07-04 |
Rubius Therapeutics, Inc. |
Gene editing and targeted transcriptional modulation for enginerering erythroid cells
|
|
US20230158070A1
(en)
|
2018-01-30 |
2023-05-25 |
Cellectis |
Combination comprising allogeneic immune cells deficient for an antigen present on both t-cells and pathological cells and therapeutic antibody against said antigen
|
|
MX2020008272A
(es)
|
2018-02-08 |
2020-09-21 |
Sangamo Therapeutics Inc |
Nucleasas diseñadas específicas de blancos.
|
|
EP3775237A1
(en)
|
2018-04-05 |
2021-02-17 |
Juno Therapeutics, Inc. |
T cells expressing a recombinant receptor, related polynucleotides and methods
|
|
KR20210029707A
(ko)
|
2018-04-05 |
2021-03-16 |
주노 쎄러퓨티크스 인코퍼레이티드 |
재조합 수용체를 발현하는 세포의 생산 방법 및 관련 조성물
|
|
US11786554B2
(en)
|
2018-04-12 |
2023-10-17 |
Precision Biosciences, Inc. |
Optimized engineered nucleases having specificity for the human T cell receptor alpha constant region gene
|
|
JP7447014B2
(ja)
|
2018-04-13 |
2024-03-11 |
サンガモ セラピューティクス フランス |
インターロイキン２３受容体に特異的なキメラ抗原受容体
|
|
WO2019204457A1
(en)
|
2018-04-18 |
2019-10-24 |
Sangamo Therapeutics, Inc. |
Zinc finger protein compositions for modulation of huntingtin (htt)
|
|
WO2019210153A1
(en)
|
2018-04-27 |
2019-10-31 |
Novartis Ag |
Car t cell therapies with enhanced efficacy
|
|
US11690921B2
(en)
|
2018-05-18 |
2023-07-04 |
Sangamo Therapeutics, Inc. |
Delivery of target specific nucleases
|
|
WO2019237035A1
(en)
|
2018-06-08 |
2019-12-12 |
Intellia Therapeutics, Inc. |
Compositions and methods for immunooncology
|
|
JP7438988B2
(ja)
|
2018-06-13 |
2024-02-27 |
ノバルティス アーゲー |
Ｂｃｍａキメラ抗原受容体及びその使用
|
|
AU2019318135A1
(en)
|
2018-08-10 |
2021-03-04 |
Sangamo Therapeutics France |
New car constructs comprising TNFR2 domains
|
|
KR102712986B1
(ko)
|
2018-08-23 |
2024-10-07 |
상가모 테라퓨틱스, 인코포레이티드 |
조작된 표적 특이적 염기 편집기
|
|
US11389485B2
(en)
|
2018-08-28 |
2022-07-19 |
Vor Biopharma Inc. |
Genetically engineered hematopoietic stem cells and uses thereof
|
|
AU2019344927A1
(en)
|
2018-09-18 |
2021-04-01 |
Sangamo Therapeutics, Inc. |
Programmed cell death 1 (PD1) specific nucleases
|
|
EP4613367A1
(en)
|
2018-09-21 |
2025-09-10 |
Acuitas Therapeutics, Inc. |
Systems and methods for manufacturing lipid nanoparticles and liposomes
|
|
MX2021003435A
(es)
|
2018-09-28 |
2021-06-15 |
Massachusetts Inst Technology |
Moleculas inmunomoduladoras localizadas en el colageno y metodos de las mismas.
|
|
CA3125485A1
(en)
|
2019-01-11 |
2020-07-16 |
Acuitas Therapeutics, Inc. |
Lipids for lipid nanoparticle delivery of active agents
|
|
WO2020205838A1
(en)
|
2019-04-02 |
2020-10-08 |
Sangamo Therapeutics, Inc. |
Methods for the treatment of beta-thalassemia
|
|
EP3959320A1
(en)
|
2019-04-24 |
2022-03-02 |
Novartis AG |
Compositions and methods for selective protein degradation
|
|
AU2020265749A1
(en)
|
2019-05-01 |
2022-01-06 |
Juno Therapeutics, Inc. |
Cells expressing a chimeric receptor from a modified CD247 locus, related polynucleotides and methods
|
|
SG11202111360YA
(en)
|
2019-05-01 |
2021-11-29 |
Juno Therapeutics Inc |
Cells expressing a recombinant receptor from a modified tgfbr2 locus, related polynucleotides and methods
|
|
CA3141159A1
(en)
|
2019-05-21 |
2020-11-26 |
Sangamo Therapeutics, Inc. |
Controlled transgene expression in regulatory t cells
|
|
US11642409B2
(en)
|
2019-06-26 |
2023-05-09 |
Massachusetts Insttute of Technology |
Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
|
|
WO2021028359A1
(en)
|
2019-08-09 |
2021-02-18 |
Sangamo Therapeutics France |
Controlled expression of chimeric antigen receptors in t cells
|
|
EP3808766A1
(en)
|
2019-10-15 |
2021-04-21 |
Sangamo Therapeutics France |
Chimeric antigen receptor specific for interleukin-23 receptor
|
|
BR112022009181A2
(pt)
*
|
2019-11-25 |
2022-07-26 |
Univ Kyoto |
Sistema para prover um produto de célula t, métodos para produzir um produto de célula t, para construir um banco celular e uma coleção de produto de célula t e para prover um produto de célula t, banco celular, coleções de banco celular e de produto de célula t, e, produto de célula t
|
|
WO2021173612A1
(en)
|
2020-02-26 |
2021-09-02 |
Sorrento Therapeutics, Inc. |
Activatable antigen binding proteins with universal masking moieties
|
|
IL296242A
(en)
|
2020-03-10 |
2022-11-01 |
Massachusetts Inst Technology |
Methods for producing engineered memory-like nk cells and preparations containing them
|
|
WO2021183207A1
(en)
|
2020-03-10 |
2021-09-16 |
Massachusetts Institute Of Technology |
COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY OF NPM1c-POSITIVE CANCER
|
|
KR20230004510A
(ko)
|
2020-03-20 |
2023-01-06 |
인썸(인스티튜트 내셔날 드 라 싼테 에 드 라 리셰르셰메디칼르) |
인간 cd45rc에 특이적인 키메라 항원 수용체 및 이의 용도
|
|
WO2021202832A1
(en)
*
|
2020-04-03 |
2021-10-07 |
Progenitor Life Sciences |
Targeting tapasin and tap complex to improve cellular immune-compatibility
|
|
US20230167191A1
(en)
|
2020-04-24 |
2023-06-01 |
Sorrento Therapeutics, Inc. |
Memory Dimeric Antigen Receptors (mDARs)
|
|
US20210340524A1
(en)
|
2020-05-01 |
2021-11-04 |
Massachusetts Institute Of Technology |
Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
|
|
US12433954B2
(en)
|
2020-05-01 |
2025-10-07 |
Massachusetts Institute Of Technology |
Methods of activating anti-CD19 chimeric antigen receptor (CAR) T cells using amphiphilic ligand conjugates comprising CAR-targeting protein sequence motifs
|
|
JP2023526278A
(ja)
|
2020-05-13 |
2023-06-21 |
ジュノー セラピューティクス インコーポレイテッド |
組み換え受容体を発現しているドナーバッチ細胞を産生するための方法
|
|
KR20230024967A
(ko)
|
2020-06-11 |
2023-02-21 |
노파르티스 아게 |
Zbtb32 억제제 및 이의 용도
|
|
US20230227901A1
(en)
|
2020-06-26 |
2023-07-20 |
The Regents Of The University Of California |
Selective Addition of Reagents to Droplets
|
|
EP4171616A1
(en)
|
2020-06-26 |
2023-05-03 |
Juno Therapeutics GmbH |
Engineered t cells conditionally expressing a recombinant receptor, related polynucleotides and methods
|
|
DK4182297T3
(da)
|
2020-07-16 |
2025-12-01 |
Acuitas Therapeutics Inc |
Kationiske lipider til brug i lipid-nanopartikler
|
|
JP2023549780A
(ja)
|
2020-11-04 |
2023-11-29 |
ジュノー セラピューティクス インコーポレイテッド |
改変されたインバリアントｃｄ３免疫グロブリンスーパーファミリー鎖遺伝子座からキメラ受容体を発現する細胞ならびに関連するポリヌクレオチドおよび方法
|
|
MX2023005609A
(es)
|
2020-11-13 |
2023-05-29 |
Novartis Ag |
Terapias de combinacion con celulas que expresan receptores quimericos para el antigeno (car).
|
|
AR125199A1
(es)
|
2021-03-23 |
2023-06-21 |
Iovance Biotherapeutics Inc |
Edición génica cish de linfocitos infiltrantes de tumores y usos de los mismos en inmunoterapia
|
|
AU2022277649A1
(en)
|
2021-05-21 |
2023-11-30 |
Cellectis S.A. |
Enhancing efficacy of t-cell-mediated immunotherapy by modulating cancer-associated fibroblasts in solid tumors
|
|
EP4347810A4
(en)
*
|
2021-05-24 |
2025-06-04 |
Sangamo Therapeutics, Inc. |
ZINC FINGER NUCLEASES TARGETING CIITA
|
|
US12305184B2
(en)
|
2021-09-03 |
2025-05-20 |
North Carolina State University |
Compositions and methods for conferring resistance to geminivirus
|
|
WO2023081715A1
(en)
|
2021-11-03 |
2023-05-11 |
Viracta Therapeutics, Inc. |
Combination of car t-cell therapy with btk inhibitors and methods of use thereof
|
|
WO2023081900A1
(en)
|
2021-11-08 |
2023-05-11 |
Juno Therapeutics, Inc. |
Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods
|
|
CN118632860A
(zh)
|
2021-11-24 |
2024-09-10 |
诺华股份有限公司 |
腺相关病毒转导调节剂及其用途
|
|
WO2023114943A2
(en)
|
2021-12-16 |
2023-06-22 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
WO2023183434A2
(en)
*
|
2022-03-22 |
2023-09-28 |
Artisan Development Labs, Inc. |
Compositions and methods for generating cells with reduced immunogenicty
|
|
JP2025525389A
(ja)
*
|
2022-06-23 |
2025-08-05 |
エヌクロマ・バイオ，インコーポレーテッド |
Ｃｉｉｔａ発現のエピジェネティック調節のための組成物及び方法
|
|
AU2023298102A1
(en)
|
2022-06-30 |
2024-11-14 |
Cellectis S.A. |
Enhancing safety of t-cell-mediated immunotherapy
|
|
WO2024086591A2
(en)
*
|
2022-10-17 |
2024-04-25 |
The Regents Of The University Of California |
Stem cell based delivery of tumor-specific retroviral vectors
|
|
JP2025536578A
(ja)
|
2022-11-03 |
2025-11-07 |
セレクティス ソシエテ アノニム |
Ｔ細胞媒介免疫療法の有効性及び安全性の増進
|
|
EP4615960A1
(en)
|
2022-11-09 |
2025-09-17 |
C3S2 GmbH |
Methods for manufacturing engineered immune cells
|
|
WO2024102954A1
(en)
|
2022-11-10 |
2024-05-16 |
Massachusetts Institute Of Technology |
Activation induced clipping system (aics)
|
|
CN121002052A
(zh)
|
2023-02-03 |
2025-11-21 |
C3S2 有限公司 |
用于非病毒生产工程化免疫细胞的方法
|
|
WO2025101877A1
(en)
*
|
2023-11-08 |
2025-05-15 |
The Children's Hospital Of Philadelphia |
Platform for increasing hla class i antigen presentation utilizing engineered chaperone fusion proteins
|
|
WO2025235862A1
(en)
|
2024-05-10 |
2025-11-13 |
Inndura Therapeutics Inc. |
A modified immune cell receptor comprising a target-binding domain and the extracellular domain of cd16a
|
|
WO2025235851A1
(en)
|
2024-05-10 |
2025-11-13 |
Juno Therapeutics, Inc. |
Genetically engineered t cells expressing a cd19 chimeric antigen receptor (car) and uses thereof for allogeneic cell therapy
|